Ariel R. Topletz‐Erickson

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

Erica Stringer-Reasor, Barbara O’Brien, Ariel R. Topletz‐Erickson et al. · Journal of Clinical Oncology · 2021 · 31 citations

Medicine, Oncology, Pharmacology +17

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects

Ariel R. Topletz‐Erickson, Anthony Lee, JoAl Mayor et al. · The Journal of Clinical Pharmacology · 2020 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

Andrew L. Coveler, David C. Smith, Tycel Phillips et al. · Journal for ImmunoTherapy of Cancer · 2023 · 21 citations · Full text

Medicine, Oncology, Pharmacology +16

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

Ariel R. Topletz‐Erickson, Anthony Lee, Evelyn Rustia et al. · Clinical Pharmacokinetics · 2022 · 16 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl

Hao Sun, Kristen A. Cardinal, Larry C. Wienkers et al. · Cancer Chemotherapy and Pharmacology · 2022 · 13 citations

Medicine, Medicinal Chemistry, Pharmacology +12